 
 
 
 
 
NCT Number : [STUDY_ID_REMOVED]  
 
 
Certain information within this protocol has been redacted (i.e., specific content is masked  
irreversibly from view with a black bar) to protect either personally identifiable information or  
company confidential information.  
 
 
This may include, but is not limited to, redaction of the following:  
 
• Named persons or organizations associated with the study.  
• Proprietary information, such as scales or coding systems.  
• Other information as needed to protect confidentiality  of BridgeBio Pharma, Sentynl 
Therapeutics, Inc., or their partners, or to otherwise protect the integrity of the clinical 
study.  
Protocol ALXN1101- MCD -201, Amendment 7.0 03 January 2020 
 
Origin Biosciences, Inc.—Confidential  Page 3 of 71 
 INVESTIGATOR’S AGREE MENT 
I have received and read the Investigator’s Brochure for ORGN001 (formerly ALXN1101). I 
have read the ALXN1101- MCD -201 study protocol and agree to conduct the study as outlined. I 
agree to maintain the confidentiality of all information received or develop ed in connection with 
this protocol. I agree to conduct the trial in accordance with ethical principles that have their 
origin in the Declaration of Helsinki and are consistent with the International Council for Harmonisation (ICH)/Good Clinical Practice ( GCP) and applicable regulatory requirements. 
      
______________________________________________ 
Printed Name of Investigator       
______________________________________________  _____________ 
Signature of Investigator      Date  
 
Protocol ALXN1101- MCD -201, Amendment 7.0 03 January 2020 
 
Origin Biosciences, Inc.—Confidential  Page 5 of 71 
 SYNOPSIS 
Name of Sponsor/Company: Origin Biosciences, Inc. (Origin); previously; Alexion Pharma ceuticals, Inc. 
(Alexion)  
Name of Investigational Product:  ORGN001 (formerly ALXN1101)  
Name of Active Ingredient: Cyclic pyranopterin monophosphate monohydrobromide dihydrate  
Title of Study: A Phase 2, Multicenter, Multinational, Open -Label, Dose -Escalation Study to Evaluate the 
Safety and Efficacy of ORGN001 (formerly ALXN1101) in Pediatric Patients with Molybdenum Cofactor 
Deficiency (MoCD) Type A Currently Treated with Recombinant Escherichia coli -derived Cyclic Pyranopterin 
Monophosphate (rcPMP ) 
Study centers: This will be a multicenter, multinational study with approximately 5 investigational study 
centers.  
Principal Investigator:  TBD  
Investigators:  TBD  
Studied period:  
6-Month Initial Treatment Period, followed by a n Extension Period  
Estimated date first patient enrolled: February 2014  
Estimated date last patient completed: The Extension P eriod  is expected to last until 
ORGN001 is commercially available or development is stopped.  Phase of 
development:  
2/3 
Study Rationale  
Molybdenum cofactor deficiency (MoCD) is a rare, life- threatening, autosomal recessive, inborn error of 
metabolism characterized by disruption of the metabolic pathway for production of molybdenum cofactor 
(MoCo), which is essential for the function of sulfite oxidase (SO),  dehydrogenase, and aldehyde 
oxidase. While all 3 enzymes are dependent on MoCo, the loss of SO activity is responsible for the severe and rapidly progressive neurologic damage seen in MoCD.  
The incidence of MoCD is estimated to be between 1/100,000 and 1/200,000 newborn babies worldwide (Schwahn 2015). Affected individuals usually present as neonates with severe symptoms such as intractable seizures, burst -suppression or multifocal electroencephalogram (EEG), exaggerated startle reactions, axial 
hypotonia, limb hypertonia, and feeding difficulties. Neuronal injury is severe and is rapidly progressive as a result of accumulation of toxic levels of sulfite in the brain and subsequent formation of S -sulfocysteine (SSC). 
Death commonly occurs in the neonatal period, and patients who survive that period develop a severe static encephalopathy and developmental delay due to central nervous system (CNS) injury including subcortical cystic cavitation, hydrocephalus, diffuse cortical atrophy, and basal ganglia injury. At present, there is no cure.  
Although there are 3 types of MoCD, two -thirds of MoCD patients have Type A, which is due to a mutation in 
the MOCS1 gene localized on 6p21.3. In MoCD Type A, the first of the 4 synthetic steps in t he formation of 
MoCo is interrupted, and guanosine triphosphate (GTP) cannot be converted into cyclic pyranopterin monophosphate (cPMP). Diagnosis of MoCD Type A is based on clinical presentation and biochemical 
phenotype (such as elevated urinary sulfite and/or SSC, and low or absent uric acid in the urine or plasma), and 
diagnosis is then confirmed by genetic testing.  
ORGN001 (cyclic pyranopterin monophosphate monohydrobromide dihydrate), provides a therapeutic approach for the treatment of MoCD Type A by  restoring the MoCo biosynthesis. Results of preclinical pharmacology 
studies with ORGN001  suggest that the metabolic derangement in MoCD Type A could be corrected by 
administration of synthetic cPMP, resulting in restoration of enzymatic activity and thus, correction of the metabolic pathways that would otherwise lead to the accumulation of toxic metabolites causing CNS injury.  

Protocol ALXN1101- MCD -201, Amendment 7.0 03 January 2020 
 
Origin Biosciences, Inc.—Confidential  Page 9 of 71 
 Statistical methods: 
The statistical analysis of all safety and efficacy parameters will be conducted on all patients who receive at least 
1 dose of ORGN001. All data collected in this study will be documented using summary tables, figures and patient data listings. For categorical variables, frequencies and percentages will be presented. For continuous 
variables, descriptive statistics (n, mean, median, standard deviation [SD], minimum, and max imum) will be 
presented. 
Safety:  
The incidence of treatment -emergent AEs and SAEs will be summarized by System Organ Class (SOC) and 
Preferred Term overall, by severity, and by relationship to study drug. Changes from baseline in vital signs, 
laboratory as sessments (chemistry, hematology, and urinalysis) will be summarized. Shifts from baseline in 
laboratory assessments as well as physical examination findings will be summarized for the different time points.  
Efficacy:  
Changes from baseline in urine and blo od SSC levels and percentage changes from baseline to the study time 
points will be summarized. Observed values and changes in Bayley -III cognitive, gross, fine motor scaled scores 
and cognitive and motor composite scores will be summarized. The frequency of seizures will be summarized. Shifts from baseline in clinical findings from neurologic examinations and neuroimaging findings will be presented for the different time points. Growth parameters (body weight, body length, and head circumference) 
will be c onverted to age -adjusted z- scores and summarized over time. Graphical displays will be presented as 
appropriate.  
Pharmacokinetics:  
Plasma concentration versus time profiles will be graphically summarized. Noncompartmental PK parameters 
such as C max, tmax, AUC, and t ½ will be determined if possible, and, dose linearity will be explored. Plasma 
concentration and PK parameter summaries will include descriptive statistics, as appropriate.  
 
Additional details for statistical analyses will be described in the statistical analysis plan.  

Protocol ALXN1101- MCD -201, Amendment 7.0 03 January 2020 
 
Origin Biosciences, Inc.—Confidential  Page 10 of 71 
 SUMMARY OF CHANGES  
 
Section  Description of Change  
1.3 Risk/Benefit Assessment  Additional text:  
“In vitro  and preclinical studies have identified that 
ORGN001 has phototoxic potential. Patients and caregivers 
are instructed to avoid direct sunlight and to use precautions when exposed to the sun. Protective measures include 
wearing of sunglasses, a hat, long s leeved shirts, long pants 
and the use of protective sunscreen.”  
Protocol ALXN1101- MCD -201, Amendment 7.0 03 January 2020 
 
Origin Biosciences, Inc.—Confidential  Page 11 of 71 
 TABLE OF CONTENTS  
ALXN1101 -MCD -201 ........................................................................................................1  
SPONSOR SIGNATURE PA GE ......................................................................................2  
INVESTIGATOR’S AGREE MENT  ................................................................................3  
PROCEDURES IN CASE OF EMERGENCY  ...............................................................4  
SYNOPSIS  ..........................................................................................................................5  
SUMMARY OF CHANGES  ...........................................................................................10  
TABLE OF CONTENTS  ................................................................................................11  
LIST OF ABBREVIATION S AND DEFINITIONS OF  TERMS  ..............................15  
1 INTRODUCTION ....................................................................................................17  
1.1 Background ..........................................................................................................17  
1.2 Rationale for the Study  ........................................................................................17  
1.3 Risk/Benefit Assessment  ......................................................................................18  
1.4 Rationale for the Patient Population ..................................................................19  
1.5 Rationale for Proposed Dosing ...........................................................................19  
1.6 Rationale for the Overall Design  ........................................................................20  
1.7 Clinical Studies with ORGN001  .........................................................................20  
2 TRIAL OBJECTIVES AND ENDPOINTS  ...........................................................21  
2.1 Objectives ..............................................................................................................21  
2.1.1  Primary Objective  ..........................................................................................21  
2.1.2  Secondary Objectives .....................................................................................21  
  
2.2 Endpoints  ..............................................................................................................21  
2.2.1  Safety Endpoints  ............................................................................................21  
2.2.2  Efficacy Endpoints .........................................................................................21  
2.2.3  Pharmacokinetic Endpoint  ...........................................................................22  
  
3 INVESTIGATIONAL PLAN  ..................................................................................23  
3.1 Overall Study Design ...........................................................................................23  
3.2 NUMBER OF PATIENTS  ..................................................................................24  
3.3 Study Treatment and Dose Escalations .............................................................24  
3.4 SAFETY REVIEW COMMITTEE ...................................................................25  
3.4.1  Criteria to Hold Dose Escalation ..................................................................25  
3.4.2  Safety Criteria for Unscheduled Dose Adjustments  ...................................26  
3.5 Criteria for Site or Study Termination  ..............................................................26  
4 SELECTION AND WITHDRAWAL OF PATIENTS  .........................................37  
4.1 Patient Recruitment and Consent  ......................................................................37  
4.2 Patient Inclusion Criteria  ....................................................................................37  
4.3 Patient Exclusion Criteria  ...................................................................................37  
4.4 Patient Withdrawal Criteria  ...............................................................................37  
5 TREATMENT OF PATIENTS ...............................................................................39  
5.1 Description of Study Drug  ..................................................................................39  
5.2 Prior and Concomitant Medications and Procedures  ......................................39  
5.3 Treatment Compliance  ........................................................................................39  
6 STUDY DRUG MATERIALS  AND MANAGEMENT  ........................................40  
6.1 Study Drug  ............................................................................................................40  
6.2 Study Drug Packaging and Labeling  .................................................................40  

Protocol ALXN1101- MCD -201, Amendment 7.0 03 January 2020 
 
Origin Biosciences, Inc.—Confidential  Page 12 of 71 
 6.3 Study Drug Storage..............................................................................................40  
6.4 Study Drug Preparation ......................................................................................40  
6.5 Study Drug Administration ................................................................................40  
7 STUDY DRUG ACCOUNTABIL ITY ....................................................................41  
7.1 Study Drug Handling and Disposal  ....................................................................41  
8 SCREENING ASSESSMENT S ...............................................................................41  
8.1 Inform ed Consent  ................................................................................................41  
8.2 Demographic Data and Onset of Disease ...........................................................41  
8.3 Medical History, Family History, and Genotype ..............................................41  
9 EFFICACY ASSESSMENTS  ..................................................................................41  
9.1 Neurol ogic Examinations ....................................................................................42  
9.2 Bayley Scales of Infant and Toddler Development ...........................................42  
9.3 THE GROSS MOTOR FUNCTION CLASSIFICATION SYSTEM  .............42  
9.4 Wechsler Preschool and Primary Scale of Intelligence ....................................43  
9.5 Seizure Diary  ........................................................................................................43  
9.6 Neuroimaging .......................................................................................................43  
9.7 Growth Parameters  .............................................................................................43  
9.8 Feeding Pattern Assessment ................................................................................43  
10 PHARMACODYNAMIC ASSE SSMENTS  ...........................................................44  
11 PHARMACOKINETIC ASSE SSMENTS  .............................................................46  
12 SAFETY ASSESSMENTS  .......................................................................................48  
12.1  Vital Signs  .............................................................................................................48  
12.1.1  Additional Blood Pressure Measurements  ..................................................48  
12.2  Physical Examination ..........................................................................................48  
12.3  Laboratory Assessments ......................................................................................49  
12.3.1  Hematology .....................................................................................................49  
12.3.2  Serum Chemistry  ...........................................................................................49  
12.3.3  Coagulation .....................................................................................................50  
12.3.4  Urinalysis  ........................................................................................................50  
12.4  Electroencephalogram .........................................................................................50  
12.5  Adverse Event Management  ...............................................................................50  
12.5.1  Definition of an Adverse Event  .....................................................................50  
12.5.2  Definition of a Serious Adverse Event  .........................................................51  
12.5.3  Severity Assessment  .......................................................................................52  
12.5.4  Causality Assessment  .....................................................................................52  
12.5.5  Outcome  ..........................................................................................................53  
12.5.6  Recording Adverse Events  ............................................................................53  
12.5.7  Reporting of Serious Adverse Events to Sponsor .......................................54  
12.5.8  Reporting Requirements  ...............................................................................54  
13 STATISTICAL METHODS AND PLANNED ANALYSES  ................................56  
13.1  General Considerations .......................................................................................56  
13.2  Determination of Sample Size  .............................................................................56  
13.3  Analysis Population .............................................................................................56  
13.4  Demographics and Baseline Characteristics  .....................................................56  
13.5  Patient Disposition and Treatment Compliance  ...............................................56  
13.6  Prior and Concomitant Medications  ..................................................................56  
13.7  Efficacy Analyses .................................................................................................56  
13.7.1  Primary Efficacy Analysis .............................................................................56  
Protocol ALXN1101- MCD -201, Amendment 7.0 03 January 2020 
 
Origin Biosciences, Inc.—Confidential  Page 13 of 71 
 13.7.2  Secondary Efficacy Analyses ........................................................................57  
  
13.8  Safety Analyses .....................................................................................................57  
13.8.1  Adverse Events  ...............................................................................................57  
13.8.2  Laboratory Parameters  .................................................................................58  
13.8.3  Physical Examinations and Vital Signs ........................................................58  
13.8.4  Electroencephalograms  .................................................................................58  
13.9  Pharmacokinetic Analysis ...................................................................................58  
13.10  Other Statistical Issues  ........................................................................................58  
13.10.1  Miss ing or Invalid Data .................................................................................58  
13.10.2  Computing Environment ...............................................................................58  
14 DIRECT ACCESS TO SOURCE DATA/DOCUMENTS  ....................................59  
14.1  Study Monitoring  .................................................................................................59  
14.2  Audits and Inspections  ........................................................................................59  
14.3  Institutional Review Board .................................................................................59  
15 QUALITY CONTROL AND QUALITY ASSURANCE  ......................................60  
16 ETHICS  .....................................................................................................................60  
16.1  Ethics Review  .......................................................................................................60  
16.2  Data Monitoring Committee Review  .................................................................60  
16.3  Written Informed Consent  ..................................................................................61  
16.4  Patient Data Protection  .......................................................................................61  
17 DATA HANDLING AND RECORDKEEPING ....................................................62  
17.1  Inspection of Records  ..........................................................................................62  
17.2  Retention of Records ............................................................................................62  
17.3  Retention of Biological Samples .........................................................................62  
17.4  Data Privacy  .........................................................................................................63  
18 PUBLICATION POLICY ........................................................................................63  
19 LIST OF REFERENCES  .........................................................................................64  
20 APPENDICES  ...........................................................................................................65  
APPENDIX A.  BLOOD SAMPLING VOLUM ES ...................................................66  
APPENDIX B.  BLOOD SAMPLING VOLUM ES TABLE (SCREENING 
THROUGH MONTH 6)  ...........................................................................................67  
APPENDIX C.  --BLOOD SAMPLING VOLUMES (EXTENSION PERI OD AND 
SAFETY FOLLOW -UP VISIT)  ..............................................................................69  
APPENDIX D.  BLOOD SAMPLING VOLUMES FOR UNSCHEDULED DOSE 
ADJUSTMENT  .........................................................................................................70  
 

Protocol ALXN1101- MCD -201, Amendment 7.0 03 January 2020 
 
Origin Biosciences, Inc.—Confidential  Page 14 of 71 
 LIST OF TABLES  
Table 1:  Emergency Contact Information ..............................................................4  
Table 2:  Abbreviations and Specialist Terms .......................................................15  
Table 3:  Schedule of Assessments (Screening and Month 1 of the 6 -Month Initial 
Treatment Period)  ....................................................................................28  
Table 4: Schedule of Assessments (Months 2 through 6 of the 6 -Month Initial 
Treatment Period)  ....................................................................................31  
Table 5:  Schedule of Assessments for a n Unscheduled Dose Adjustment  .........34  
Table 6:  Schedule of Assessments (Extension Period and Safety Follow -Up) ...35  
Table 7:  ORGN001 Description .............................................................................39  
Table 8:  Pharmacokinetic Sampling Schedule  .....................................................46  
Table 9:  Criteria for Child -Pugh Classification ...................................................48  
Table 10:  Blood Sampling Volumes (Screening Through Month 6)  ....................67  
Table 11:  Sample Volume Collection During the Extension Period and Safety 
Follow --Up Visit  .......................................................................................69  
Table 12:  Sample Volume Collection for an Unscheduled Dose Adjustment  .....70  
 
LIST OF FIGURES  
Figure  1: ALXN1101 -MCD -201 Study Design ......................................................27  
 
Protocol ALXN1101- MCD -201, Amendment 7.0 03 January 2020 
 
Origin Biosciences, Inc.—Confidential  Page 15 of 71 
 LIST OF ABBREVIATION S AND DEFINITIONS OF  TERMS  
The following abbreviations and specialist terms are used in this study protocol. 
Table 2: Abbreviations and Speciali st Terms  
Abbreviation  Definition  
1H NMR  Proton nuclear magnetic resonance spectroscopy  
13C NMR  Carbon nuclear magnetic resonance spectroscopy  
31P NMR  Phosphorous nuclear magnetic resonance spectroscopy  
AE Adverse event  
Alexion  Alexion Pharma GmbH  
AUC Area under the plasma concentration -time curve  
BP Blood pressure  
Bayley -III Bayley Scales of Infant and Toddler Development -Third Edition  
°C Degrees Celsius  
Cmax Maximum observed plasma concentration  
CNS Central nervous system  
Colbourne  Colbourne Pharmaceuticals GmbH  
cPMP  Cyclic pyranopterin monophosphate  
CRF Case Report Form  
CT Computed tomography  
CYP 450  Cytochrome P450  
DMC  Data Monitoring Committee  
EC Ethics Committee  
E. coli  Escherichia coli  
eCRF  Electronic Case Report Form 
EEG Electroencephalogram  
EMLA  Eutectic mixture of local anesthetics  
EOI End of infusion  
EOS  End of study  
FAS Full Analysis Set  
GCP Good Clinical Practice  
GMFCS  Gross Motor Function Classification System  
GMP Good Manufacturing Practice  
GTP Guanosine triphosphate  
IB Investigator’s Brochure  
ICF Informed Consent Form  
ICH International Council for Harmonisation  
IEC Independent Ethics Committee  
INR International normalized ratio  
IRB Institutional Review Board  
IV Intravenous  
LC-MS/MS  Liquid chromatography with tandem mass spectrometric detection  
MoCD  Molybdenum cofactor deficiency  
MedDRA  Medical Dictionary for Regulatory Activities  
MoCo  Molybdenum cofactor  
MPT Molybdopterin  
MRI Magnetic resonance imaging  
MS Mass spectroscopy  
MSDS  Material Safety Data Sheet  
N Normal  
NOAEL  No observed adverse effect level  
Origin  Origin Biosciences, Inc.  
PD Pharmacodynamics  
Protocol ALXN1101- MCD -201, Amendment 7.0 03 January 2020 
 
Origin Biosciences, Inc.—Confidential  Page 16 of 71 
 PI Principal Investigator  
PK Pharmacokinetics  
PT Prothrombin time  
RBC Red blood cell  
rcPMP  Recombinant E. coli -derived cPMP  
SAE Serious adverse event  
SAP Statistical analysis plan  
SD Standard deviation  
SO Sulfite oxidase  
SOC System Organ Class  
SRC Safety Review Committee  
SSC S-sulfocysteine  
t1/2 Terminal half -life 
tmax Time to maximum observed plasma concentration  
UK United Kingdom  
US United States (of America)  
UV Ultraviolet (spectroscopy)  
WBC  White blood cell  
WHODrug  World Health Organization Drug Dictionary  
WPPSI  Wechsler Preschool and Primary Scale of Intelligence  
Protocol ALXN1101- MCD -201, Amendment 7.0 03 January 2020 
 
Origin Biosciences, Inc.—Confidential  Page 17 of 71 
 1 INTRODUCTION 
1.1 Background 
Molybdenum cofactor deficiency (MoCD) is a rare, life-threatening, autosomal recessive, inborn 
error of metabolism characterized by disruption of the metabolic pathway for production of molybdenum cofactor (MoCo), which is essential for the function of sulfite oxidase (SO), xanthine dehydrogenase, and aldehyde oxidase. While all 3 enzymes are dependent on MoCo, the loss of SO activity is responsible for the severe and rapidly progressive neurologic damage seen in MoCD. 
The incidence of MoCD is estimated to be between 1/100,000 and 1/200,000 newborn babies worldwide ( Schwahn 2015). Affected individuals usually present in the neonatal period with 
intractable seizures, b urst--suppression or multifocal epileptic electroencephalogram (EEG), 
exaggerated startle reactions, axial hypotonia, limb hypertonia, and feeding difficulties ( Johnson 
and Duran 2001; Kikuchi et al, 2012; Vijayakumr et al, 2011). Neuronal injury is severe and is rapidly progressive as a result of accumulation of toxic levels of sulfite in the brain and subsequent formation of S-sulfocysteine (SSC). Death commonly occurs in the neonatal period, and patients who survive that period develop a severe static encephalopathy and developmental delay due to central nervous system (CNS) injury including subcortical cystic cavitation, hydrocephalus, diffuse cortical atrophy, and basal ganglia injury (Johnson and Duran 2001; Johnson et al, 1980).  
Three types of MoCD have been described based on the genetic defect. Two -thirds of MoCD 
patients have Type A, which is due to a mutation in the MOCS1 gene localized on 6p21.3 and results in the interruption of the first of the 4 synthetic steps in the formation of MoCo; guanosine triphosphate (GTP) cannot be converted into cyclic pyranopterin monophosphate (cPMP). Diagnosis of MoCD Type A is based on clinical presentation (encephalopathy, seizures) and biochemical phenotype (elevated urinary sulfite and SSC, and low or absent uric acid in the urine or plasma). The diagnosis is then confirmed by genetic testing. At present, there is no approved t herapy available and no cure.  
A treatment targeting MoCo biosynthesis represents a possible therapeutic strategy to treat MoCD Type A. A cPMP substitution therapy is expected to reconstitute MoCo biosynthesis and restore SO levels, thereby reducing the lev els of the neurotoxic compounds, sulfite and SSC. 
1.2 Rationale for the Study  
The previous sponsor, Alexion Pharma GmbH (Alexion) developed ORGN001 (formerly ALXN1101), a synthetic form of cPMP, which is a precursor molecule to MoCo, as a treatment for MoCD Ty pe A.  Responsibility for the development of ORGN001 for the treatment of MoCD 
Type A has been assumed by Origin Biosciences, Inc.  ORGN001 provides a therapeutic approach for the treatment of MoCD Type A that is intended to restore MoCo biosynthesis. Resu lts of preclinical pharmacology studies with ORGN001 suggest that the metabolic 
derangement in MoCD Type A could be corrected by administration of synthetic cPMP, resulting in restoration of enzymatic activity and thereby correction of the metabolic pathwa ys 
that lead to the accumulation of toxic metabolites causing CNS injury.  
In vitro, ORGN001 increased molybdopterin (MPT) synthesis and restored SO activity (Clinch  et al, 2013). Additionally, in a mouse model of M oCD Type A ( Lee et al, 2002), 
ORGN0
01 effectively rescued MOCS1 -/- mice from premature death and effectively decreased 
the plasma SSC level.  In  repeat dose-toxicity studies in adult rats and dogs, ORGN001 

Protocol ALXN1101- MCD -201, Amendment 7.0 03 January 2020 
 
Origin Biosciences, Inc.—Confidential  Page 26 of 71 
 3.4.2 Safety Criteria for Unscheduled Dose Adjustments  
Doses may be adjusted based on the occurrence of drug- related  AEs and changes in clinical 
parameters, as assessed by the S RC. The SRC chair will also convene the DMC if a dose 
escalation is being considered or will notify the DMC if the dose is decreased. If a patient has 
significant clinical worsening related to ORGN001 dosing, the dose may be decreased based on the clinical  status of the patient and, if available, exposure data. If this occurs within the 
first 2  months, the target dose reduction would be approximately 25% of the starting dose 
 or
 to a level that is 
expec
ted to result in exposure that is below the NOAEL AUC. If an unscheduled dose 
adjustment is necessary during Months 2 through 6 of the study, the patient’s dose will be reduced to the last tolerated dose.  Alternatively, after dose escalation is complete, the patient 
can be returned to a prior dose based on the patient’s clinical status at the discretion of the treating physician after consultation  with the SRC.  
3.5 Criteri
a for Site or Study Termination  
For reasonable cause, the Investigator, Institutional Review Board (IRB)/Ethics Committee (EC), 
or Sponsor may terminate the study at a given center, in which case, the care of the patients at 
the site would be transferred to a different Investigator, or all centers, in which case, patients would return to the care of their treating physician. Conditions that may warrant termination of 
the study or investigational sites participating in this study include, but are not limited  to: 
• Discovery of an unexpected, serious, or unacceptable risk to patients enrolled in the study 
• Decision on the part of the Sponsor to suspend or discontinue testing, evaluation, or development of the study drug 
• Failure of the Investigator to comply with the approved protocol, pertinent guidelines, and/or regulations 
• Submission of knowingly false information from the Investigator to the Sponsor and/or regulatory authorities  
The end of the study will be defined as the date of the last patient’s last visit.

Protocol ALXN1101- MCD -201, Amendment 7 .0 03 January 2020 
 
Origin Biosciences, Inc.—Confidential  Page 28 of 71 
 Table 3: Schedule of Assessments (Screening and Month 1 of the 6 -Month Initial Treatment  Period)  
Assessment  Screening/  
Baseline Period1,2 Month 1 of the 6 -Month Initial Treatment Period  
Study Day  
Month  
Visit Window (Days)  
Informed consent  
Eligibility  
Demographic data and onset of disease5 
Genotype7 
Family history8 
Medical history9 
Physical examination25 
Vital signs12,25 
Additional BP measurements  
Serum chemistry and hematology13, 25 
Coagulation14 
Urinalysis15, 25 
Growth parameters16 
Feeding pattern17 
Neurologic examination25 
GMFCS  
Bayley -III (age -appropriate test)19 
WPPSI20 
Record seizure diary data21, 25 
Neuroimaging22 
EEG23 
PD sampling, urine24,25 

Protocol ALXN1101- MCD -201, Amendment 7 .0 03 January 2020 
 
Origin Biosciences, Inc.—Confidential  Page 31 of 71 
 medications; MoCD = molybdenum cofactor deficiency; MRI = magnetic resonance imaging; PD = pharmacodynamics; PI = principal investigator; PK = 
pharmacokinetics; rcPMP = recombinant E. coli- derived cPMP; SRC = Safety Review Committee; SSC = S -sulfocysteine; WPPSI = Wechsler Preschool and 
Primary Scale of  Intelligence.  
 
Protocol ALXN1101- MCD -201, Amendment 7 .0 03 January 2020 
 
Origin Biosciences, Inc.—Confidential  Page 33 of 71 
 22 Daily IV infusion of ORGN001 (24 hours  ± 3 hours  apart) can occur at home or while in -clinic  
23 Changes in seizure medications, including the reason for the change, will be recorded.  
24 Assessed only if the patient is seen in -clinic. An in -clinic visit is not required for blood and urine  collection on this day.  
Abbreviations: AEs = adverse events; Bayley -III = Bayley Scales of Infant and Toddler Development -Third Edition; CRF = case report form;  
EEG = electroencephalogram; eCRF = electronic case report form; EOI = end of infusion; GMFCS = Gross Motor Function Classification System;  
meds = medications; MRI = magnetic resonance imaging; PD = pharmacodynamics; PK = pharmacokinetics; rcPMP = recombinant E. co li-derived cPMP; SRC 
= Safety Review Committee; SSC = S -sulfocysteine; WPPSI = Wechsler Preschool and Primary Scale of Intelligence.  
 
Protocol ALXN1101- MCD -201, Amendment 7.0 03 January 2020 
 
Origin Biosciences, Inc.—Confidential  Page 38 of 71 
 All patients who discontinue or are withdrawn from the study will be encouraged to complete the 
Safety Follow -up Visit . 
The reasons for premature study withdrawal must be recorded in the patient’s case repo rt form 
(CRF)/electronic case report form (eCRF) and in the source records.  
For patients who are prematurely withdrawn from the study due to clinical safety concerns (eg, 
intolerable AEs), the Investigator must immediately notify the Medical Monitor. In these 
patients, AEs leading to premature withdrawal must be followed until resolution or the patient is determined to be medically stable, in the opinion of the Investigator. Patients who withdraw from the study will not be  replaced.  

Protocol ALXN1101- MCD -201, Amendment 7.0 03 January 2020 
 
Origin Biosciences, Inc.—Confidential  Page 42 of 71 
 9.1 Neurologic Examinations 
Neurologic examinations will be performed  . The 
Day 1 assessment must be performed within 2  hours prior to the first infusion. Neurologic 
examinations are also performed if patients have unscheduled dose adjustments  
. Neurologic examination includes, but is not limited to, 
assessment of mental status, cranial nerves, motor strength and tone, sensory examination, deep 
tendon reflexes and primitive reflexes, if present.  
9.2 Bayley Scales of Infant and Toddler Development 
The Bayley Scales of Infant and Toddler Development-Third Edition (Bayley- III) will be 
administered  to assess changes in gross motor, fine 
motor, language, and cognitive development. The Bayley -III will be administered to children 
less than 3 years of age. Additionally, for patients over 3 years of age with severe developmental delay, the Bayley- III may be more appropriate than the WPPSI and may therefore be 
administered instead.  
The Bayley -III is a standardized and norm- referenced instrument that assesses changes in gross 
motor, fine motor, language, and cognitive development. It is administered in infants and 
children 1 month to 42 months of age. 
The Bayley -III consists of a core battery of the following 5 scales, 3 of which are administered 
by a trained qualified professional with child interaction: the Cognitive Scale, the Language 
Scale (including  the Receptive Communication and Expressive Communication subtests), and 
the Motor Scale (including the Fine Motor and Gross Motor subtests). The Social- Emotional 
Scale and Adaptive Behavior Scale together form the Social -Emotional and Adaptive Behavior 
Questionnaire, which is completed by the parent, legal guardian, or primary caregiver. This 
caregiver -administered portion of the Bayley- III will not be administered as part of this study. 
The Bayley -III assessments must be performed in the order specified in the Bayley- III Manual.  
The Language Scale will be administered only to native English speakers in English-speaking countries. 
From raw scores, scaled scores, developmental age equivalents, and growth scores can be 
calculated for the Cognitive, Receptive and Expressive Communication , Fine Motor, and Gross 
Motor subtests. Scaled scores also can be used to calculate the Cognitive, Language, and Motor composite scores, percentile ranks, and confidence intervals. 
A qualified professional will administer the Bayley -III and determine the appropriateness of each 
assessment.
 
9.3 THE GROSS MOTOR FUNCTION CLASSIFICATION SYSTEM  
Gross motor function using the GMFCS will be assessed  
. 
The GMFCS is a 5 -level classification system that describes the gross motor function of children 
and youth (up to 18 years of age ) on the basis of their self -initiated  movement with particular 
emphasis on sitting, walking, and wheeled mobility for children with impaired motor skills.  
Distinctions between levels are based on functional abilities, the need for assistive technology, 
including hand- held mobility devices (wa lkers, crutches, or canes) or wheeled mobility, and to a 
much lesser extent, quality of movement.  
Children who have motor functions similar to those classified in "Level I" can generally walk without restrictions but tend to be limited in some of the more advanced motor skills. Children 

Protocol ALXN1101- MCD -201, Amendment 7.0 03 January 2020 
 
Origin Biosciences, Inc.—Confidential  Page 51 of 71 
 • Leads to a change in study dosing outside of the protocol defined 
dosing or discontinuation from the study;  
• Requires significant additional treatment;  
• Does not meet any of the conditions above; however, the Investigator or Sponsor considers the result as clinically significant or meeting the definition 
of an  AE. 
This definition also includes the signs or symptoms resulting from: 
• Drug  overdose 
• Drug  withdrawal  
• Drug  misuse  
• Drug  interactions  
• Extravasation  
• Medication  error  
• Occupational  exposure 
An AE does not necessarily include the following:  
• Medical or surgical procedures (eg, surgery, endoscopies, tooth extraction, 
transfusion); the condition that leads to the procedure is the AE (eg, 
laparoscopic cholecystectomy is the procedure or treatment for an SAE of necrotic gall  bladder);
 
• Pre-existing diseases or conditions present or detected prior to the 
Screening evaluation that do not worsen; 
• Situations where an untoward medical occurrence has not occurred (eg, 
hospitalization for elective surgery if planned prior to the start of the study,  
social and/or convenience admissions). 
12.5.2 Definition of a Serious Adverse Event  
Any AE that fulfills any one of the criteria listed below must be recorded as an SAE.  An SAE is 
described as  any untoward medical occurrence that at any dose:  
Results in  death  
Is life-threatening  
Requires hospitalization or prolongation of hospitalizationb  
Hospitalization does not necessarily include the following: 
• Rehabilitation/hospice/nursing facility  
• Emergency Room/Department visit less than 24  hours 
• Elective or preplanned admission/surgery/ Day surgery  
• Protocol- specified  admission  
• Admission for a pre-existing condition not associated with either a new AE or 
with worsening of a pre- existing  AE 
Results in persistent or significant disability/incapacity  
Protocol ALXN1101- MCD -201, Amendment 7.0 03 January 2020 
 
Origin Biosciences, Inc.—Confidential  Page 52 of 71 
 Is a congenital anomaly/birth  defect  
Is an important medical eventc 
a. The term "life -threatening" in the definition of "serious" refers to an event in which the 
patient was at risk of death at the time of the event; it does not refer to an event which 
hypothetically might have caused death if  it were more  severe.  
b. Hospitalization requires inpatient or prolongation of an existing hospitalization. AEs that are associated with hospitalization or prolongation of hospitalization are considered SAEs.  
c. Important Medical Event: Medical and scientific judgment should be exercised in deciding whether expedited reporting is appropriate in other situations, such as important medical events that may  not be immediately life -threatening or  result  in death or hospitalization 
but may jeopardize the patient or may require intervention to prevent one of the other outcomes listed in the definition above. These should also usually be considered serious. Examples of such events are intensive treatment in an emergency room or at home for allergic bronchospasm; blood dyscrasias or convulsions that do not result in hospitalization; or development of drug dependency.  
Severity and seri ousness must be differentiated. Severity describes the intensity of an AE while 
the term seriousness refers to an AE that has met the criteria for an SAE as described above.  
12.5.3 Severity Assessment  
An assessment of severity will be made by the Investigator using the following criteria:  
• Mild: events require minimal or no treatment and do not interfere with the  
patient’s daily  activities.  
• Moderate: events result in a low level of inconvenience or concerns with the therapeutic measures. Moderate events may cause some interference 
with functioning. 
• Severe: events interrupt a patient’s usual daily activity and may require systemic 
drug therapy or other treatment. Severe events are usually  incapacitating.  
Change in severity of an AE should be documented based on specific guidance in the eCRF 
Completion Guidelines. 
Severity and seriousness must be differentiated: severity describes the intensity of an AE while 
seriousness refers to an AE that has met the criteria for an SAE.  
12.5.4 Causality Assessment  
An Inves tigator causality assessment must be provided for all AEs (both nonserious and serious). 
This assessment must be recorded on the CRF/eCRF and any additional forms as appropriate. 
The definitions for the causality assessments are as follows: 
• Not related (un related): This relationship suggests that there is no association 
between the study drug and the reported event.  
• Unlikely related: This relationship suggests that the clinical picture is highly 
consistent with a cause other than the study drug,  but attribution cannot be made 
with absolute certainty and a relationship between the study drug and AE cannot be excluded w ith complete  confidence. 
• Possibly related: This relationship suggests that treatment with the study drug 
may have caused or contributed to the AE, ie, the event follows a reasonable 
Protocol ALXN1101- MCD -201, Amendment 7.0 03 January 2020 
 
Origin Biosciences, Inc.—Confidential  Page 53 of 71 
 temporal sequence from the time of drug administration and/or follows a 
known response pattern to the study drug but could also have been produced by 
other factors.  
• Probably related: This relationship suggests that a reasonable temporal sequence of the event with the study drug administration exists and the likely association of 
the event with the study drug. This will be based upon the known pharmacological action of the study drug, known or previously reported adverse reactions to the study drug or class of drugs, or judgment based on the Principal Investigator’s clinical  experience.  
• Definitely related: Temporal relationship to the study drug. Other conditions 
(concurrent illness, concurrent medication reaction, or 
progression/expression of disease state) do not appear to explain event, corresponds with the known pharmaceutical profile, improvement on discontinuation, re-appearance on re- challenge.  
12.5.5 Outcome  
For all AEs, regardless of causal relationships, the Investigator must follow-up on the outcome of 
the event until the event or sequelae either resolves or stabi lizes.  
If a patient experiences a SAE with an outcome of death:  
• The SAE resulting in death should have an outcome documented as death/fatal with an end date being the date of  death. 
• If the patient had additional AEs/SAEs that were ongoing at the time of de ath, these events 
would be documented as ongoing with no end date.  
• Only 1 event should have an outcome of death/fatal unless an autopsy report or Investigator 
states  otherwise.  
12.5.6 Recording Adverse Events  
All observed or volunteered AEs regardless of causal relationship must be reported as described in Section 12.5.4. 
For all AEs, the Investigator must obtain adequate information for the following: 
1. determine the outcome of the AE; 
2. determine if the event meets criteria for an  SAE;  
3. assess the severity of the  AE; 
4. determine the causality of the  AE. 
Adverse events must be documented in clear, unambiguous medical term. Study personnel are 
advised not to use abbreviations or acronyms.  
For each AE, record only the diagnosis on the AE page of the CRF/eCRF. Do not report the characteristic signs and symptoms of the diagnosis as additional AEs. 
If a diagnosis is not available, record each sign and symptom as an AE. When a diagnosis 
becomes available, study personnel are to update the source document and the AE page of the CRF/eCRF with relevant diagnosis only. 
Protocol ALXN1101- MCD -201, Amendment 7.0 03 January 2020 
 
Origin Biosciences, Inc.—Confidential  Page 54 of 71 
 For medical or surgical procedures (eg, surgery, endoscopies, tooth extraction, transfusion), the 
condition/diagnosis that leads to the procedure should be recorded as the AE (eg, laparoscopic cholecystectomy is the procedure or treatment for an SAE of necrotic gall bladder).  
All AEs that later increase in the frequency and/or severity (medical and sci entific judgment 
should be exercised by the Investigator) will be considered new AEs and will be recorded on a new line in source and the CRF/eCRF.  
Withdrawal due to an AE or SAE must be clearly differentiated from withdrawal due to other reasons.
 
12.5.7 Reportin g of Serious Adverse Events to Sponsor 
All AEs must be assessed by the Investigator to determine if they meet criteria for an SAE. All SAEs must be reported to the Sponsor or designee immediately or within 24 hours of the Investigator or their staff becoming aware of them regardless of the presumed relationship to the study drug. 
The Investigator must complete, sign, and date the SAE pages, verify the accuracy of the 
information recorded on the SAE pages with the corresponding source documents, and send a copy via email or fax to the contact information provided  
 
When further information becomes available, the SAE Form should be updated with the new information and reported immediately via the same contact information. 
Additional follow-up information, if required or available, should be entered into the CRF/eCRF 
and sent to the Sponsor within 24 hours of the Investigator site or their staff becoming aware of this additional information via the reporting process outlined above. These reporting timelines need to be followed for all initial SAE cases and follow-up versions of the initial cases. 
For all SAEs the Investigator must provide the following: 
• Clear identification of the Investigator/Reporter with full c ontact information, country and 
site number 
• Subject identification details (subject’s unique study identification number) 
• Investigational Medicinal Product(s) administration details (dose and dates) Seriousness 
criteria  
• Appropriate and requested follow-up information in the time frame detailed  above 
• Causality of the serious events 
• Outcome of the serious events 
• Medical records and laboratory / diagnostic information 
12.5.8 Reporting Requirements  
This protocol will use the current IB as the Reference Safety Document. The expectedness and reporting criteria of an SAE will be determined by the Sponsor from the Reference Safety Document. 
12.5.8.1 Sponsor Reporting Requirements  
The Sponsor or its legal representative is responsible for notifying the relevant 
regulatory au thorities  of SAEs meeting the reporting criteria.  

Protocol ALXN1101- MCD -201, Amendment 7.0 03 January 2020 
 
Origin Biosciences, Inc.—Confidential  Page 55 of 71 
 12.5.8.2 Investigator Reporting Requirements  
The Investigator must fulfill all local regulatory obligations required for the study Investigators. 
It is the PI’s responsibility to notify the IRB or Independent Ethics Committee (IEC) of all SAEs that occur at his or her site. Investigators will also be notified of all unexpected, serious, drug--related events (7/15 Day  Safety Reports) that occur during the clinical study. Each site is 
responsible for notifying its IRB or IEC (if local) of these additional SAEs. Investigators will receive blinded information unless unblinded information is judged necessary for safety reasons. 
Protocol ALXN1101- MCD -201, Amendment 7.0 03 January 2020 
 
Origin Biosciences, Inc.—Confidential  Page 56 of 71 
 13 STATISTICAL METHODS AND PLANNED ANALYSES 
13.1 General Considerations  
Data collected during the study will be presented in summary tables, figures, or by- patient data 
listings. Continuous variables will be summarized using mean, standard deviation (SD), median, 
minimum, and maximum. Categorical variables will be summarized using percentages and frequ ency  distributions. No formal hypothesis testing will be performed. 
13.2 Determination of Sample Size  
At least 4 MoCD Type A patients will be enrolled in the study. The actual sample size 
will depend on the number of eligible patients currently being treated wi th rcPMP.  
13.3 Analysis Population 
Efficacy analyses will be performed on the Full Analysis Set (FAS). Due to the small number of 
patients, a Per -Protocol Population will not be utilized for this study. The FAS will include all 
patients who receive at least 1 d ose of ORGN001. 
Safety analyses will be performed on the Safety Set, defined as all patients who receive at least 1 dose of ORGN001. 
13.4 Demographics and Baseline Characteristics  
All demographic and baseline characteristics information will be summarized for all patients. 
For categorical variables, frequencies and percentages will be presented. Continuous variables will be summarized  using descriptive statistics (mean, median, SD, and minimum and  
maximum).  
13.5 Patient Disposition and Treatment Compliance  
The number of patients screened, treated, completing the 6 -Month Initial Treatment Period, and 
included in the safety and efficacy analysis sets will be tabulated by counts and percentage of 
patients. Reasons for any patient withdrawals will be provided. 
Treatment compliance with ORGN001 will be presented for all patients. 
13.6 Prior and Concomitant Medications  
Prior and concomitant medications will be summarized using the Safety Set. Listings of prior 
and concomitant medications will be produced as will listings of seizu re medications.  
Medications will be coded using the World Health Organization Drug Dictionary (WHODrug) version 01 September 2013 or higher. Medication summaries will be presented by WHODrug Anatomical Therapeutic Chemical (ATC) and by WHODrug generic name . 
13.7 Efficacy Analyses 
Efficacy analyses will be performed on the FAS.  
13.7.1 Primary Efficacy Analysis 
There is no prespecified primary efficacy endpoint in this study. Secondary efficacy analyses are described in Section  13.7.2 . 

Protocol ALXN1101- MCD -201, Amendment 7.0 03 January 2020 
 
Origin Biosciences, Inc.—Confidential  Page 58 of 71 
 Treatment -emergent AEs are AEs that begin after the start of ORGN001. Treatment -emergent 
AEs will be summarized by incidence, Preferred Term, System Organ Class (SOC), seriousness, 
severity, relationship to treatment.  
All AEs will be summarized by both event counts and patient counts. For patient counts, if a patient has more than one occurrence of an AE for a specific Preferred Term or SOC, the patient will be counted only once for that Preferred Term or SOC. The most severe occurrence of an AE as well as the most extreme relationship of the AE will be indicated in cases of multiple occurrences of the same AE at onset of the AE.  
13.8.2 Laboratory Parameters  
Changes from Baseline in laboratory assessments (chemistry and hematology) will be summarized  by visit, and shift tables (L [low], N [normal], H [high]) by visit will be produced 
for clinical laboratory tests.  
13.8.3 Physical Examinations and Vital Signs 
Physical examinations and Child -Pugh scores (A [a score of 5 to 6], B [a score of 7 to 9], C [a 
score of 10 or above]) will be summarized by visit. Vital signs (systolic and diastolic BP, temperature, heart rate, and respiratory rate) and changes from baseline in vital signs will be summarized by visit.  
13.8.4 Electroencephalograms  
The number and percentage of patients with EEG findings will be summarized by visit.  
13.9 Pharmacokinetic Analysis 
Plasma concentration versus time profiles will be graphically summarized. Non -compartmental 
PK parameters such as C
max, tmax, AUC, and t ½ will be determined if possible, and dose linearity 
will be explored. Plasma concentration and PK parameter summaries will include descriptive statistics, as appropriate. Details of PK analyses will be presented in an analysis plan.  
13.10 Other Statistical Issues  
13.10.1 Missing  or Invalid Data 
If a date of a measurement or an event has a missing or an unknown day, the missing or unknown Day  will be substituted by 15 for the calculation of other variables such as age at which 
the measurement was taken, or the age at the occurrenc e of an event. If the month or the year of a 
date is missing, no imputation will take place. In general, other missing or invalid observations will not be replaced or imputed unless otherwise specified in the SAP.  
13.10.2 Computing Environment  
Efficacy and safety analyses will be performed using SAS for windows, Version 9.2 or higher (SAS Institute Inc., Cary, NC, USA). 
PK ana
lyses will be performed using Phoenix WinNonlin versi
on 6.3 or higher (Pharsight, Cary, 
NC, USA)
. 
Protocol ALXN1101- MCD -201, Amendment 7.0 03 January 2020 
 
Origin Biosciences, Inc.—Confidential  Page 59 of 71 
 14 DIRECT ACCESS TO SOURCE DATA/DOCUMENTS  
14.1 Study Monitoring 
A representative of the Sponsor or designee may visit the investigational study site to: 
• Determine the adequacy of the facilities and  equipment 
• Discuss with the Investigators and other personnel their responsibilities with regard to 
protocol adherence, and the responsibilities of the Sponsor or its representatives. This will be documented in a Clinical Study Agreement between the Sponsor and the Investigator. 
During the study, a representative of the Sponsor or designee will have regular contac t with 
the investigational site, for the following : 
• Provide information and support to the Investigators  
• Confirm that facilities and equipment remain  acceptable 
• Confirm that all patients have been properly consented 
• Confirm drug accountability 
• Confirm that the investigational team is adhering to the protocol, that data are being accurately recorded in the CRFs/eCRFs, and that study drug accountability checks are being  
performed  
• Perform source data verification. This includes a comparison of the data in the CRFs/eCRFs with the patient’s medical records at the hospital or practice, and other records relevant to the study. This will require direct access to all original records for each patient (eg, clinic  charts).  
• Record and report any protocol deviations not previously sent to the Sponsor. 
• Confirm AEs and SAEs have been properly documented on CRFs/eCRFs and confirm any SAEs have been forwarded to the Sponsor and those SAEs that met criteria for reporting 
have been forwarded to the IRB.  
The monitor will be available between visits if the Investigators or other staff needs 
information  or advice.  
14.2 Audits and Inspections  
Authorized representatives of the Sponsor, a regulatory authority, an IEC or an IRB may visit the 
site to perform audits or inspections, including source data verification. The purpose of an audit or inspection by the Sponsor is to systematically and independently examine all study- related 
activities and documents to determine whether these activities were conducted, and data w ere 
recorded, analyzed, and accurately reported according to the protocol, Good Clinical Practice (GCP) guidelines of the International Council for Harmonisation (ICH), and any applicable regulatory requirements. The Investigator should contact the Sponsor immediately if contacted by a regulatory agency about an inspection.
 
14.3 Institutional Review Board 
The PI must obtain IRB/IEC approval for the investigation. All IRB/IEC approvals, including initial and continued review, and all materials approved by the IRB/IEC for this study including the patient consent form and recruitment materials must be maintained by the Investigator and made available for inspection. 
Protocol ALXN1101- MCD -201, Amendment 7.0 03 January 2020 
 
Origin Biosciences, Inc.—Confidential  Page 60 of 71 
 15 QUALITY CONTROL AND QUALITY ASSURANCE  
To ensure compliance with GCP and all applicable regulatory req uirements, the Sponsor or 
designee may conduct quality assurance audits  (Section 14.2).  
16 ETHICS 
This study will be performed in accordance with ethical principles that have their origin in the 
Declaration of Helsinki and are consistent with ICH GCP guidelines. 
Investigators and other study personnel must comply with all instructions and regulations 
specified in this protocol and applicable ICH GCP guidelines and must conduct this study in accordance with all local, federal, and regulatory agency regulations.  
In accordance to ICH guidelines, pediatric participation in these studies should occur in qualified pediatric centers, with personnel who are properly trained and ex perienced in studying the 
pediatric population and in evaluating and managing potential pediatric AEs. Site personnel should be knowledgeable and skilled in dealing with the pediatric population and its age- appropriate needs and be encouraged to use measures that minimize discomfort of procedures ( e.g., topical anesthesia to place IV catheters, use of indwelling catheters instead of 
repeated venipunctures for blood sampling, and collection of some protocol-specified blood samples when routine clinical samples are obtained).
 
16.1 Ethics Review  
The final study protocol, including the final version of the ICF, must be approved or given a favorable opinion in writing by an IRB or IEC as appropriate. The Investigator must submit written approval to the Sponsor before he or she can enroll any patient into the study. 
No modifications to the protocol should be made without the approval of both the Investigator 
and the Sponsor. Changes that significantly affect patient safety, the scope of investigation, or the scientific  validity of the study will require IRB/IEC notification prior to implementation, 
except where the modification is necessary to eliminate an apparent immediate hazard to patients. Any deviations from protocol must be fully documented. The PI is responsible for informing the IRB or IEC of any amendment to the protocol in accordance with local requirements. In addition, the IRB or IEC must approve all advertising used to recruit patients for the study. The protocol must be re-approved by the IRB or IEC upon r eceipt of amendments 
and annually, as local regulations require. 
The PI is also responsible for providing the IRB with reports of any reportable serious adverse 
drug reactions from any other study conducted with the study drug. The Sponsor will provide this information to the PI. 
Progress reports and notifications of serious adverse drug reactions will be provided to the IRB 
or IEC according to local regulations and guidelines. 
16.2 Data Monitoring Committee Review  
An independent DMC will be appointed by the Sponsor  
 who have no direct relationship with the 
study.  
P
rior t
o each scheduled dose escalation, the SRC chair will convene the DMC to review 
laboratory and clinical data in conjunction with the SRC to determine if dose escalation is 
appropriate ( Section 3.4). 

Protocol ALXN1101- MCD -201, Amendment 7.0 03 January 2020 
 
Origin Biosciences, Inc.—Confidential  Page 61 of 71 
 Final decisions regarding the conduct of the study will be made by the Sponsor after consultation 
with the DMC. All appropriate regulatory authorities and ECs will be notified of any significant action.  
The DMC may be asked to provide medical and ethical guidance related to the conduct of the study as described above. The DMC will review study information as outlined in the DMC charter, which is maintained separately from the study protocol. 
Each member of the DMC will be required to sign a contract agreement, which includes a 
confidentiality and financial disclosure statement, assuring no conflicts of interest as a condition for membership on the board.
 
16.3 Written Informed Consent  
The PIs at each center will ensure that the patient's parent or legal guardian is given full and adequate oral and written information about the nature, purpose, possible risk and benefit of the study. The patient's parent or legal guardian must also be notified that they are free to discontinue their child from the study at any time. The parent or legal guardian should be given the opportunity to ask questions and allowed time to consider the information provided. 
The signed and dated ICF must be obtained before conducting any study procedures. 
The PIs must maintain the original, signed ICF. A copy of the signed ICF must be given to the 
patient's parent or legal guardian. 
Should new information become available during the conduct of the study that might impact 
parent or legal guardian willingness to continue participation in the study, the parent or legal guardian will be notified in a timely manner about the new information and asked to sign a new ICF.
 
16.4 Patient Data Protection  
Prior to the performance of any study-related procedures, the patient’s parent or legal guardian 
must authorize the release and use of protected health information a s required by local, federal 
and regulatory agency law. 
CRFs/eCRFs will be completed at the site either on paper or in the electronic data capture system. Copies of pertinent records in connection with the study, including patient charts and laboratory data, will be made available to the Sponsor or designee on request in a timely manner throughout the course of the study, with due precaution toward protecting patient privacy. 
Protocol ALXN1101- MCD -201, Amendment 7.0 03 January 2020 
 
Origin Biosciences, Inc.—Confidential  Page 63 of 71 
 17.4 Data Privacy  
The Sponsor will make every effort to protect patient privacy. For all study data collection, 
patients will be identified by a unique patient number and date of birth in regions where permitted. The results from this study may be presented at meetings or in articles. However, patient name or initials that could identify a patient will not be used in any such meetings or articles.  
18 PUBLICATION POLICY 
The full terms for publication are outlined in the Clinical Study Agreement, Statement of Agreement, or Master Clinical Study Agreement. Publication terms permit publication only after publication of multicenter results and require that any data to be submitted for publication including abstract submissions or presentations, be submitted to the Sponsor for review at least 30 days prior to submission. 
Protocol ALXN1101- MCD -201, Amendment 7.0 03 January 2020 
 
Origin Biosciences, Inc.—Confidential  Page 64 of 71 
 19 LIST OF REFERENCES 
Clinch K, Watt DK, Dixon RA, Baars SM, Gainsford GJ , Tiwari A, et al. Synthesis of cyclic 
pyranopterin monophosphate, a biosynthetic intermediate in the molybdenum cofactor pathway. 
J.Med.Chem. 2013 Feb 28;56(4):1730-8. 
European Commission Ethical Considerations for Clinical Trials on Medicinal Products 
Conducted with the Paediatric Population: Recommendations of the ad hoc group for the 
development of implementing guidelines for Directive 2001/20/EC relating to good clinical practice in the conduct of clinical trials on medicinal products for human use. 2008 European Commission. 2008. 
Committee for Medicinal Products for Human Use (CHMP) and Paediatric Committee (PDCO), 
Guideline on the Investigation of Medicinal Products in the Term and Preterm Neonate. 
European Medicines Agency (EMA) London, 2009 European Medicines Agency (EMA). 2009. 
Hitzert MM, Bos AF, Bergman KA, Veldman A, Schwarz G, Santamaria- Araujo JA, et al. 
Favorable outcome in a newborn with molybdenum cofactor type A deficiency treated with 
cPMP. Pediatrics. 2012 Oct;130(4):e1005-e1010. 
Johnson JL, Duran M. The Metabolic and Molecular Bases of Inherited Disease, Chapter 128, 
Molybdenum Cofa ctor Deficiency and Isolated Sulfite Oxidase Deficiency. 8 ed. McGraw -Hill; 
2001.3163-77 p. 
Johnson JL, Waud WR, Rajagopalan KV, Duran M, Beemer F, Wadman S. Inborn errors of 
molybdenum metabolism: Combined deficiencies of sulfite oxidase and xanthine dehy drogenase 
in a patient lacking the molybdenum cofactor. Proc Natl Acad Sci. 1980 Jun;77(6):3715-9. 
Kikuchi K, Hamano S, Mochizuki H, Ichida K, Ida H. Molybdenum Cofactor Deficiency Mimics 
Cerebral Palsy: Differentiating Factors for Diagnosis.  
Pediatric Neu rology. 2012 Apr 16;47:147-9. 
Lee HJ, Adham IM, Schwarz G, Kneussel M, Sass J, Engel W, et al. Molybdenum 
cofactor -deficient mice resemble the phenotype of human patients. Human Molecular Genetics. 
2002 Dec 15;11(26):3309-17. 
Schwahn BC, Galloway P, Bowhay S, Veldman A, Belaidi A, Santamaria - Araujo J, et al. 
Follow-up of two infants with molybdenum cofactor deficiency (MOCD) group A, on long- term 
treatment with cyclic pyranopterin monophosphate (cPMP). J Inherit Metab Dis. 2011;34(suppl 
3):S84. 
Schwahn BC, Spronsen FJ, Balaidi AA, Bowhay S, Christodoulou J, Derks TG, et al. Efficacy 
and safety of cyclic pyranopterin monophosphate substitution in severe molybdenum cofactor deficiency type A: a prospective cohort study. Lancet. 2015 Nov 14;386(10007):1955-63. 
Veldman A, Santamaria-Araujo JA, Sollazzo S, Pitt J, Gianello R, Yapalito- Lee J, et al. 
Successful Treatment of Molybdenum Cofactor Deficiency Type A With cPMP. Pediatrics. 2010 
May;125(5):e1249-e1254. 
Veldman A, Schwahn B, Galloway P, van Spronsen FBK, W eis I, et al. Efficacy and safety of 
cyclic pyranopterin monophosphate in the treatment of six newborn babies with molybdenum 
cofactor deficiency type A. J Inherit Metab Dis. 2011;34(suppl 3):S84. 
Vijayakumr K, Gunny R, Grunewald S, Carr L, Chong K, DeVile C, et al. Clinical 
Neuroimaging Features and Outcome in Molybdenum Cofactor Deficiency. Pediatric Neurology. 2011;45:246-52. 
 
Protocol ALXN1101- MCD -201, Amendment 7.0 03 January 2020 
 
Origin Biosciences, Inc.—Confidential  Page 65 of 71 
 20 APPENDICES  
• Appendix A  Blood Sampling Volumes (European Commission2008; European 
Medicines Agency (EMA) 2009) 
• Appendix B  Blood Sampling Volumes Table (Screening Through Month 6) 
• Appendix C  Blood Sampling Volumes Table (Extension Period and Safety  Follow- Up  
Visit)  
• Appendix D  Blood Sampling Volumes for Unscheduled Dose Adjustment 